Patents by Inventor Michael J. Holtzman

Michael J. Holtzman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF
    Publication number: 20230192728
    Abstract: Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.
    Type: Application
    Filed: July 13, 2022
    Publication date: June 22, 2023
    Applicant: Washington University
    Inventors: Michael J. Holtzman, Arthur G. Romero, Benjamin J. Gerovac, Zhenfu Han, Shamus P. Keeler, Kangyun Wu
  • Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
    Patent number: 11407771
    Abstract: Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: August 9, 2022
    Assignee: Washington University
    Inventors: Michael J. Holtzman, Arthur G. Romero, Benjamin J. Gerovac, Zhenfu Han, Shamus P. Keeler, Kangyun Wu
  • MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF
    Publication number: 20210214378
    Abstract: Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 15, 2021
    Applicant: Washington University
    Inventors: Michael J. Holtzman, Arthur G. Romero, Benjamin J. Gerovac, Zhenfu Han, Shamus P. Keeler, Kangyun Wu
  • MODIFIED STAT1 TRANSGENE THAT CONFERS INTERFERON HYPERRESPONSIVENESS, METHODS AND USES THEREFOR
    Publication number: 20100015091
    Abstract: Methods of enhancing cellular responses to interferons are disclosed. These methods comprise administering to a subject a vector comprising a Stat1-CC transgene, such as an AAV5 vector comprising a reporter operably linked to a nucleic acid sequence encoding a Stat1-CC polypeptide. The methods can be used in the treatment of diseases that involve interferon responses, such as multiple sclerosis, amyotrophic lateral sclerosis, and lupus; viral infections such as infection by hepatitis C virus, influenza A virus, cowpox virus, Sendai virus or Encephalomyocarditis virus; respiratory disorders; and cancers.
    Type: Application
    Filed: July 16, 2009
    Publication date: January 21, 2010
    Applicant: WASHINGTON UNIVERSITY IN ST. LOUIS
    Inventors: Michael J. Holtzman, Yong Zhang
  • Methods for ameliorating childhood infections
    Publication number: 20040116341
    Abstract: Methods to treat paramyxovirus infection are disclosed, which comprise administering RANTES protein or an expression system therefor. Also disclosed are methods to identify individuals susceptible to paramyxovirus infection.
    Type: Application
    Filed: January 7, 2004
    Publication date: June 17, 2004
    Inventor: Michael J. Holtzman